- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Oesophageal carcinoma or gastroesophageal junction carcinoma
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 685KB)
- Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 1982KB)
Nivolumab – November 2022
Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
Last updated
30 May 2025